BioProtection Systems Corporation (BPSC) is a biotechnology company committed to leading the global fight against bioterror agents and emerging infectious diseases.

Established in 2005, BPSC develops novel, highly potent antiviral vaccines employing the HyperAcute® αGal Technology platform that we’ve licensed from our parent company NewLink Genetics (1999). This proprietary platform is currently being tested in Phase II human clinical trials as an anti-cancer agent (HyperAcute® cancer vaccines). Our vision is to apply our HyperAcute® αGal Technology to new and existing vaccines, enabling us to combat biowarfare agents and the spread of emerging diseases.